Sigma-Aldrich Launches Search Engine - Analyst Blog

Sigma-Aldrich Corporation ( SIAL ) has announced the launch of a novel scientific search engine, especially designed to offer research workers an easy access over peer-reviewed articles and abstract information on the company's website.

The new search engine enables scientists to instantly read the entire text of millions of peer-reviewed papers without any extra clicks or logins and discover applications for specific Sigma-Aldrich products in peer-reviewed literature. It is also equipped to provide free access to the Ingenuity gene and biological pathway database. This approach enhances the scientific search process and aids the research community by finding better information.

Pubget, a solutions provider which focuses on expediting the acquisition and analysis of contents, extended its technology for accessing instant full-text papers, products and technical data, along with the methods and gene data in the search tool on the Sigma-Aldrich website. This tool is handy as it allows scientists to spend more time on doing research and save time on searching.

The Ingenuity Systems Platform powers the biological search on the Sigma-Aldrich website by using the Target Explorer web services. Target Explorer provides exclusive biological content that is advanced, comprehensive and relevant to searches conducted by scientists through the Sigma-Aldrich website.

Last month, Sigma-Aldrich posted its first-quarter 2013 adjusted earnings of $1.03 per share, above the year-ago earnings of 99 cents. The results beat the Zacks Consensus Estimate of $1.00. Profit, as reported, rose roughly 4.3% year over year to $122 million (or $1.01 per share) in the quarter from $117 million (or 96 cents per share) a year ago.

Revenues rose 1.5% year over year to $675 million in the quarter, matching the Zacks Consensus Estimate. Acquisitions added 2% to sales while foreign exchange translation had a negative impact of 1%. Sigma-Aldrich's overall end markets remained steady with improving pharma trends.

Sigma-Aldrich currently maintains a Zacks Rank #4 (Sell).

Other companies in the specialty chemical space with favorable Zacks Rank are American Pacific Corporation ( APFC ), American Vanguard Corp . ( AVD ) and Ferro Corp. ( FOE ). While American Pacific and American Vanguard hold a Zacks Rank #1 (Strong Buy), Ferro Corp retains a Zacks Rank #2 (Buy).

AMER PAC CORP (APFC): Get Free Report

AMER VANGUARD (AVD): Free Stock Analysis Report

FERRO CORP (FOE): Free Stock Analysis Report

SIGMA ALDRICH (SIAL): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.